NanoString and Abcam enter partnership to expand antibody portfolio

Abcam Australia Pty Ltd

Monday, 15 April, 2019

NanoString Technologies, a provider of life science tools for translational research and molecular diagnostic products, has announced a commercial agreement with Abcam, a global innovator in life science reagents and tools, for the manufacture and sale of antibodies specifically for use with NanoString’s GeoMx Digital Spatial Profiler (DSP).

Under the terms of the agreement, Abcam will leverage its collection of over 6000 recombinant monoclonal antibodies, validated for use with IHC in either fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue samples, to create bespoke antibody content for NanoString’s GeoMx DSP platform. This will enable GeoMx DSP users to more rapidly dissect and explore cellular interactions at a local level and facilitate discovery of novel biology.

“Researchers using our GeoMx DSP platform often want to customise their analysis,” said Brad Gray, President and CEO of NanoString. “We have partnered with Abcam to facilitate access to their broad portfolio of high-quality, validated antibodies to augment our off-the-shelf GeoMx Protein Panels. Abcam’s proven track record of antibody quality and performance was a key consideration in ensuring the success of our customer’s spatial profiling research.”

“We are excited to be partnering with NanoString to support the GeoMx DSP users’ groundbreaking research,” said John Baker, SVP of Product Portfolio and Innovation at Abcam. “Our recombinant monoclonal antibodies help ensure robust and quantitative spatial protein analysis of even the most challenging samples and may ultimately accelerate vital biomarker discoveries.”

Abcam will manufacture and sell GeoMx-formatted antibodies through its catalogue and website directly to GeoMx DSP users.

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Abcam acquires Expedeon's Proteomics and Immunology business

Abcam has announced the successful completion of the acquisition of Expedeon's Proteomics and...

First International Standard for biorisk management

ISO 35001 defines the requirements and guidance for laboratories or any other organisation that...

Do you have a technology idea that could help people with MS?

Novartis is offering a US$250,000 prize to fund development of pioneering innovation with great...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd